Determined to avoid a repeat of the supply shortfalls that plagued early GLP-1 rollouts for obesity, Eli Lilly has amassed a sizable store of its oral weight loss candidate orforglipron. Specifically, Lilly had secured “pre-launch inventories” worth $1.5 billion as
read moreFriday’s RFI sets a March 19 deadline for stakeholders to weigh in on what the government should consider when putting together its second attempt at a 340B rebate test run. More: Trump administration restarts its efforts to pilot 340B rebates
read moreA new campaign for Astellas Pharma’s Izervay is aimed at opening retina specialists’ eyes to the unique role they play in their geographic atrophy patients’ lives. More: Astellas casts retina specialists as ‘Partners in Protection’ in Izervay HCP campaign Source:
read moreVertex expects $500 million in 2026 from new products outside of its flagship cystic fibrosis franchise. In 2025, those drugs delivered a combined total of $175.6 million. More: Busy with Casgevy and Journavx launches, Vertex sets ambitious 0M revenue goal
read moreThe regulatory environment in the United States encountered by Moderna during the development of its COVID-19 vaccine bears little resemblance to what the company experienced earlier this week when the FDA refused to review its application for approval of its
read more© 1994 - 2026 B.M. Pharmaceuticals